🏅 FDA Orphan Designation
Daybue
TROFINETIDE
Manufacturer: Acadia Pharmaceuticals Inc.
Indicated for:
FDA-Approved Indications (1)
indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older
Population: adults and pediatric patients ≥2 years
Indications & Usage
1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )
💙 Support Programs
View all →Daybue
Acadia Pharmaceuticals Inc.
Daybue
Acadia Pharmaceuticals Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.